Preparation and in vivo/in vitro evaluation of formononetin phospholipid/vitamin E TPGS micelles

References

• Stewart BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer. 2014:3–11
   Google Scholar
• Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v103–15
   PubMed Web of Science ®Google Scholar
• Zhou R, Xu L, Ye M, et al. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res 2014;46:753–60
   PubMed Web of Science ®Google Scholar
• Chen J, Zeng J, Xin M, et al. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo. Horm Metab Res 2011;43:681–6
   PubMed Web of Science ®Google Scholar
• Li T, Zhao X, Mo Z, et al. Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells. Cell Physiol Biochem 2014;34:1351–8
   PubMed Web of Science ®Google Scholar
• Ye Y, Hou R, Chen J, et al. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation. Horm Metab Res 2012;44:263–7
   PubMed Web of Science ®Google Scholar
• Lo YL, Wang W. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem Biol Interact 2013;205:188–97
   PubMed Web of Science ®Google Scholar
• Jin YM, Xu TM, Zhao YH, et al. In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa. Tumour Biol 2014;35:2279–84
   PubMed Web of Science ®Google Scholar
• Liu Y, He J, Chen X, et al. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of ERK and Akt pathways. Cell Physiol Biochem 2014;34:637–45
   PubMed Web of Science ®Google Scholar
• Ma ZQ, Ji WW, Fu Q, et al. Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR Gamma expression. Inflammation 2013;36:1560–6
   PubMed Web of Science ®Google Scholar
• Vitale DC, Piazza C, Melilli B, et al. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet 2013;38:15–25
   PubMed Web of Science ®Google Scholar
• Singh SP, Wahajuddin, Tewari D, et al. PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone. Food Chem Toxicol 2011;49:1056–62
   PubMed Web of Science ®Google Scholar
• Tolleson WH, Doerge DR, Churchwell MI, et al. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J Agric Food Chem 2002;50:4783–90
   PubMed Web of Science ®Google Scholar
• Jia XB, Chen J, Lin HM, et al. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther 2004;310:1103–13
   PubMed Web of Science ®Google Scholar
• Jeong E, Jia XB, Hu M. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol Pharm 2005;2:319–28
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010;197:3–53
   PubMedGoogle Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310–16
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90–9
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012;33:4889–906
   PubMed Web of Science ®Google Scholar
• Moretton MA, Taira C, Flor S, et al. Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: in vitro characterization and in vivo evaluation. Colloids Surf B Biointerfaces 2014;123:302–10
   PubMed Web of Science ®Google Scholar
• Tang XJ, Han M, Yang B, et al. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin. Int J Pharm 2014;477:536–45
   PubMed Web of Science ®Google Scholar
• Bao Y, Guo Y, Zhuang X, et al. d-α-Tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells. Mol Pharm 2014;11:3196–209
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kulkarni SA, Xiong JQ, et al. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm 2011;421:332–40
   PubMed Web of Science ®Google Scholar
• Zhao H, Yung LY. Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting. J Biomed Mater Res A 2009;91:505–18
   PubMed Web of Science ®Google Scholar
• Klejdus B, Mikelová R, Petrlová J, et al. Evaluation of isoflavone aglycon and glycoside distribution in soy plants and soybeans by fast column high-performance liquid chromatography coupled with a diode-array detector. J Agric Food Chem 2005;53:5848–52
   PubMed Web of Science ®Google Scholar
• Klejdus B1, Mikelová R, Petrlová J, et al. Determination of isoflavones in soy bits by fast column high-performance liquid chromatographycoupled with UV–Visible diode-array detection. J Chromatogr A 2005;1084:71–9
   PubMed Web of Science ®Google Scholar
• Saadati R, Dadashzadeh S. Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation. Int J Pharm 2014;464:135–44
   PubMed Web of Science ®Google Scholar
• Rao MR, Bajaj A. Study of effect of variables on particle size of telmisartan nanosuspensions using Box–Behnken design. Drug Res (Stuttg) 2014;64:663–7
   PubMedGoogle Scholar
• Ding W, Wang F, Zhang J, et al. A novel local anti-colorectal cancer drug delivery system: negative lipidoid nanoparticles with a passive target via a size-dependent pattern. Nanotechnology 2013;24:375101
   PubMed Web of Science ®Google Scholar
• Kirchherr AK, Briel A, Mäder K. Stabilization of indocyanine green by encapsulation within micellar systems. Mol Pharm 2009;6:480–91
   PubMed Web of Science ®Google Scholar
• Munyendo WL, Zhang Z, Abbad S, et al. Micelles of TPGS modified apigenin phospholipid complex for oral administration: preparation, in vitro and in vivo evaluation. J Biomed Nanotechnol 2013;9:2034–47
   PubMed Web of Science ®Google Scholar
• Turk CT, Oz UC, Serim TM, et al. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech 2014;15:161–76
   PubMed Web of Science ®Google Scholar
• Raju A, Muthu MS, Feng SS. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv 2013;10:747–60
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang K, Wu Z, et al. Evaluation of transdermal salidroside delivery using niosomes via in vitro cellular uptake. Int J Pharm 2014;478:138–46
   PubMed Web of Science ®Google Scholar
• Lin D, Li G, Qin L, et al. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line. J Biomed Nanotechnol 2013;9:2017–23
   PubMed Web of Science ®Google Scholar
• Wang G, Yu B, Wu Y, et al. Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int J Pharm 2013;446:24–33
   PubMed Web of Science ®Google Scholar
• Chandrasekharan P, Maity D, Yong CX, et al. Vitamin E (d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials 2011;32:5663–72
   PubMed Web of Science ®Google Scholar
• Hou L, Yao J, Zhou J, et al. Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system. Biomaterials 2012;33:5431–40
   PubMed Web of Science ®Google Scholar
• Zhang L, Yao J, Zhou J, et al. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int J Pharm 2013;441:654–64
   PubMed Web of Science ®Google Scholar
• Danhier F, Kouhé TT, Duhem N, et al. Vitamin E-based micelles enhance the anticancer activity of doxorubicin. Int J Pharm 2014;476:9–15
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 2013;4:81–9
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607–12
   PubMed Web of Science ®Google Scholar
• Goutayer M, Dufort S, Josserand V, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 2010;75:137–47
   PubMed Web of Science ®Google Scholar